{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:57:35Z","timestamp":1787061455974,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002949","name":"Government of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.imlet.2020.09.001","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T11:21:05Z","timestamp":1599132065000},"page":"96-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity"],"prefix":"10.1016","volume":"227","author":[{"given":"Min","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yundi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.imlet.2020.09.001_bib0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol."},{"key":"10.1016\/j.imlet.2020.09.001_bib0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","article-title":"PD-1\/PD-L and autoimmunity: A growing relationship","volume":"310","author":"Zamani","year":"2016","journal-title":"Cell Immunol."},{"key":"10.1016\/j.imlet.2020.09.001_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.025","article-title":"PD-1 immunobiology in systemic lupus erythematosus","volume":"97","author":"Curran","year":"2019","journal-title":"J Autoimmun."},{"key":"10.1016\/j.imlet.2020.09.001_bib0020","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3389\/fimmu.2019.02298","article-title":"The Diverse Function of PD-1\/PD-L Pathway Beyond Cancer","volume":"10","author":"Qin","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.imlet.2020.09.001_bib0025","article-title":"The PD-1\/PD-L pathway in rheumatic diseases","author":"Zhang","year":"2020","journal-title":"J Formos Med Assoc."},{"issue":"6","key":"10.1016\/j.imlet.2020.09.001_bib0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/intimm\/dxq026","article-title":"PD-1 deficiency results in the development of fatal myocarditis in MRL mice","volume":"22","author":"Wang","year":"2010","journal-title":"Int Immunol."},{"issue":"7","key":"10.1016\/j.imlet.2020.09.001_bib0035","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1600-0714.2011.01035.x","article-title":"The high expression level of programmed death-1 ligand 2 in oral lichen planus and the possible costimulatory effect on human T cells","volume":"40","author":"Du","year":"2011","journal-title":"J Oral Pathol Med."},{"issue":"6","key":"10.1016\/j.imlet.2020.09.001_bib0040","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat Immunol."},{"issue":"15-16","key":"10.1016\/j.imlet.2020.09.001_bib0045","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.molimm.2011.06.436","article-title":"PD-L2 is expressed on activated human T cells and regulates their function","volume":"48","author":"Messal","year":"2011","journal-title":"Mol Immunol."},{"issue":"7","key":"10.1016\/j.imlet.2020.09.001_bib0050","first-page":"1410","article-title":"CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid","volume":"30","author":"Hatachi","year":"2003","journal-title":"J Rheumatol."},{"issue":"8","key":"10.1016\/j.imlet.2020.09.001_bib0055","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.4049\/jimmunol.171.8.4156","article-title":"Blockade of B7-H1 suppresses the development of chronic intestinal inflammation","volume":"171","author":"Kanai","year":"2003","journal-title":"J Immunol."},{"issue":"8","key":"10.1016\/j.imlet.2020.09.001_bib0060","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.imlet.2020.09.001_bib0065","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of programmed death 1 ligands by murine T cells and APC","volume":"169","author":"Yamazaki","year":"2002","journal-title":"J Immunol."},{"issue":"26","key":"10.1016\/j.imlet.2020.09.001_bib0070","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1016\/j.imlet.2020.09.001_bib0075","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J Clin Oncol."},{"issue":"21","key":"10.1016\/j.imlet.2020.09.001_bib0080","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med."},{"issue":"26","key":"10.1016\/j.imlet.2020.09.001_bib0085","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.imlet.2020.09.001_bib0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity."},{"issue":"4","key":"10.1016\/j.imlet.2020.09.001_bib0095","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice","volume":"181","author":"Lucas","year":"2008","journal-title":"J Immunol."},{"issue":"10","key":"10.1016\/j.imlet.2020.09.001_bib0100","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/eji.200838137","article-title":"PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE","volume":"38","author":"Schreiner","year":"2008","journal-title":"Eur J Immunol."},{"key":"10.1016\/j.imlet.2020.09.001_bib0105","article-title":"Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus","volume":"2009","author":"Liu","year":"2009","journal-title":"J Biomed Biotechnol"},{"issue":"2","key":"10.1016\/j.imlet.2020.09.001_bib0110","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2249.2004.02427.x","article-title":"Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjogren\u2019s syndrome and systemic sclerosis","volume":"136","author":"Hebbar","year":"2004","journal-title":"Clin Exp Immunol."},{"issue":"6","key":"10.1016\/j.imlet.2020.09.001_bib0115","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0961203308099176","article-title":"Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus","volume":"18","author":"Her","year":"2009","journal-title":"Lupus."},{"issue":"1","key":"10.1016\/j.imlet.2020.09.001_bib0120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","article-title":"The PD-1\/PD-Ls pathway and autoimmune diseases","volume":"290","author":"Dai","year":"2014","journal-title":"Cell Immunol."},{"issue":"2","key":"10.1016\/j.imlet.2020.09.001_bib0125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13317-010-0011-7","article-title":"The soluble CTLA-4 receptor and its role in autoimmune diseases: an update","volume":"1","author":"Saverino","year":"2010","journal-title":"Auto Immun Highlights."},{"issue":"10","key":"10.1016\/j.imlet.2020.09.001_bib0130","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.4049\/jimmunol.1300587","article-title":"B7h triggering inhibits the migration of tumor cell lines","volume":"192","author":"Dianzani","year":"2014","journal-title":"J Immunol."},{"key":"10.1016\/j.imlet.2020.09.001_bib0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cca.2016.12.017","article-title":"Complement in autoimmune diseases","volume":"465","author":"Vignesh","year":"2017","journal-title":"Clin Chim Acta."},{"issue":"2","key":"10.1016\/j.imlet.2020.09.001_bib0140","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4103\/JLP.JLP_171_17","article-title":"Complement deficiency in pediatric-onset systemic lupus erythematosus","volume":"10","author":"Afzali","year":"2018","journal-title":"J Lab Physicians."},{"key":"10.1016\/j.imlet.2020.09.001_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: Diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J Autoimmun."},{"issue":"9","key":"10.1016\/j.imlet.2020.09.001_bib0150","first-page":"e3288","article-title":"Systemic Lupus Erythematosus: An Overview of the Disease Pathology and Its Management","volume":"10","author":"Ali","year":"2018","journal-title":"Cureus."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247820303801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247820303801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:39:22Z","timestamp":1759045162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247820303801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":30,"alternative-id":["S0165247820303801"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2020.09.001","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2020.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}